TA-8995-206
Brief description of study
Requesting a reliance agreement with an external IRB. The primary objective is to evaluate the efficacy of obicetrapib alone for 8 weeks as compared to obicetrapib in combination with Evolocumab for an additional 8 weeks after initial obicetrapib treatment on percent change of Lp(a) levels from Baseline in people with mild dyslipidemia, defined as Lp(a) levels 50 mg/dL ( 125 nmol/L) and LDL-C levels 70 mg/dL ( 1.8 mmol/L) and 190 mg/dL ( 4.91 mmol/L).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
